Amgen Inc.


SKU: AMGN-1 Category:


Amgen delivered strong volume-driven growth in the last quarter which resulted in the company managing an all-around beat. Many of the innovative products of the company performed quite well, namely Evenity, Prolia, Otezia, and Repatha, all of which delivered sales growth of double-digits. Two of the company’s new products, Tezspire and Lumakras, are both off to a great start. Lumakras is being prescribed to patients with non-small cell cancer worldwide. Meanwhile, Tezspire has made a large impact in quite a short period of time on a wide population of patients who have severe asthma in the United States. The planned acquisition of ChemaCentryx will add another recently launched innovative product to the portfolio of the company, Tavbeos, that is for ANCA-associated vasculitis, which is a life-threatening and serious autoimmune disease. The company’s Blincyto, Nplate, and Kyprolis in its innovative hematology oncology portfolio generated record quarterly sales. Across general medicine, oncology, and information, the company has a wide portfolio of biosimilar and innovative products that meet the patients’ needs globally. The company has recently declared positive results from its study of Dahlia. It has also posted positive data from the biosimilar study of Soliris. Overall, there appears to be a lot to look forward to in Amgen and we provide the stock with a ‘Hold’ rating with a revision in the target price.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!